An interventional study of Embosphere Microspheres and Corticosteroid injection in Knee Osteoarthritis, sponsored by Merit Medical Systems, Inc.. Terminated at 17 sites in 4 countries. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Merit Medical Systems, Inc. · Not applicable, Interventional, and Treatment
How we know · 4 judgments
Sponsor decision to terminate the study.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 796 studies in Osteoarthritis, Knee with a site in United States — 109 open to participants now, 152 under way, 15 of them phase 3. Osteoarthritis, Knee · United States.
Among the 796 studies in Osteoarthritis, Knee with a site in United States, this one is the 414th largest by enrollment of the 691 interventional ones that give a count, is one of 31 that started in 2024, is one of 376 with no phase, and was the 679th registered.
3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.
Browse Osteoarthritis, Knee studies →109 of the 796 studies in Osteoarthritis, Knee with a site in United States are open now. Recruiting first, the newest first:
Lucas R. Cusumano, MD · Sites in United States
Ages 40+
VA Office of Research and Development · Sites in United States
Ages 18+
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States, Canada
Ages 18+
Margaret L Gourlay, MD, MPH · Sites in United States
Ages 50–64
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
796 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 60 · Phase 2 146 · Phase 3 89 · Phase 4 59
First in 1977; this study’s year is marked. 31 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 52 is below the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 72 across the 691 interventional studies, 100 across the 101 observational. Of the 566 that completed or were terminated, 247 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
265 of 796 have an industry lead sponsor. The 10 most frequent:
Merit Medical Systems, Inc. is the lead sponsor of 29 studies on the registry; 4 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 6 (86%) have results posted.
Merit Medical Systems, Inc. has 1 study filed under Osteoarthritis, Knee — fewer than ten, so there is no comparison to draw.
54 of the studies in Osteoarthritis, Knee with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07226258Phase 3Saol Therapeutics IncPhase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee Pain | 2026-11-30 |
| NCT07219771Phase 3Doron Therapeutics Inc.A Study to Evaluate the Efficacy and Safey of PTP-001 (MOTYS™) in Knee Osteoarthritis Patients (MOTION-P) | 2027-06-30 |
| NCT06917404Phase 3Paradigm Biopharmaceuticals Ltd.A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain. | 2027-07 |
| NCT04368806Phase 3Nature Cell Co. Ltd.A Phase 2b/3a Study to Evaluate the Efficacy and Safety of JointStem in Patients Diagnosed as Knee Osteoarthritis | 2027-08-06 |
| NCT07151417Phase 3Walter Reed National Military Medical CenterUse of Corticosteroid in Intraopertive Injections in Total Knee Replacement Surgery. | 2027-08-31 |
Add all 54 to your calendar (.ics) → With an account.
Among the 796 studies in Osteoarthritis, Knee with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This multicenter, prospective, interventional trial is designed to assess the outcome of subjects with symptomatic knee osteoarthritis (OA) that are randomized to treatment with either genicular artery embolization (GAE) using Embosphere Microspheres or steroid injection over a period of 24 months.
This study is an IDE study. It is an RCT comparing GAE to steroid injection in the knee to treat knee osteoarthritis.
Key Inclusion Criteria:
Provides written
Age ≥21 years
Mild to severe knee pain, defined as a WOMAC Pain score of ≥8 out of 20 (in the target knee)
Pain to conservative therapies for at least 90 days prior to enrollment/randomization.
Kellgren-Lawrence grade 1, 2, 3 or 4
Key Exclusion Criteria:
Planned major surgical or endovascular procedures ≤ 30 days after the index procedure.
Advanced atherosclerosis
Known history of rheumatoid or infectious arthritis.
Prior knee replacement surgery of the target knee.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Embosphere Microspheres Embolic Agent: Embosphere Microspheres
Device: Embosphere Microspheres
Drug: Corticosteroid injection
Drug: Corticosteroid injection
Embolic Agent: Embosphere Microspheres
Also known as: Genicular artery embolization
Corticosteroid injection
Also known as: Triamcinolone or methylprednisolone
Primary Efficacy Endpoint
Clinical Success defined as ≥50% improvement in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale from baseline to 6 months without the need for additional intervention.
Time frame: 6 months
Primary Safety Endpoint
Freedom from treatment-related safety events through 6 months (180 days) following the index procedure.
Time frame: 6 months
Subjects achieving Clinical Success
Number of subjects achieving Clinical Success
Time frame: 3, 12, and 24 months
Numerical rating scale (NRS)
Pain score assessed using numerical rating scale (NRS)
Time frame: baseline, 3, 6, 12 and 24 months
Plan to share: No
Ran from Jan 2024 to primary completion in May 2026, 28 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Apr 2026 → May 2026 and completion Oct 2027 → May 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Sponsor decision to terminate the study.
Sponsor decision to terminate the study.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.